New Clinical Guideline for 18F-Flurpiridaz PET Myocardial Perfusion Imaging and Blood Flow Quantitation Issued

Strategic Insights -

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Society of Nuclear Cardiology (ASNC), European Association of Nuclear Medicine (EANM), and American College of Nuclear Medicine (ACNM) have issued a new clinical guideline for 18F-flurpiridaz PET myocardial perfusion imaging (MPI) and blood flow quantitation. The guideline is intended to assist nuclear cardiology practitioners in the optimal application of 18F-flurpiridaz PET for MPI, including recommendations for patient selection, imaging protocols, and interpretation of results. The guideline has been co-published in The Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.

Key Takeaways:

  • The new clinical guideline for 18F-flurpiridaz PET MPI and blood flow quantitation has been issued by SNMMI, ASNC, EANM, and ACNM.
  • The guideline is intended to assist nuclear cardiology practitioners in the optimal application of 18F-flurpiridaz PET for MPI.
  • The guideline includes recommendations for patient selection, imaging protocols, and interpretation of results.
  • 18F-flurpiridaz is a novel PET radiotracer that has demonstrated favorable imaging and physiological properties compared to conventional SPECT agents.
  • Clinical studies have shown that 18F-flurpiridaz provides superior image quality, improved diagnostic accuracy, and greater sensitivity in detecting clinically significant coronary artery stenosis compared with conventional SPECT agents.
  • The guideline addresses qualifications and responsibilities of personnel performing cardiac stress testing using 18F-flurpiridaz, protocol (and potential protocol modifications), biodistribution and dosimetry, and the 18F-flurpiridaz PET workflow.
  • Technologist considerations are also included in the guideline.
  • The authors of the guideline include leading experts in nuclear cardiology and medical imaging from institutions such as UCLA, University of Montreal, and Yale University.
  • The guideline has been designed to promote high-quality, safe, and effective nuclear medicine practice in the evaluation of CAD.

Statistics:

  • The guideline has been co-published in The Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.
  • Clinical studies have shown that 18F-flurpiridaz provides superior image quality, improved diagnostic accuracy, and greater sensitivity in detecting clinically significant coronary artery stenosis compared with conventional SPECT agents.
  • The guideline includes information on clinical indications, contraindications, and considerations for 18F-flurpiridaz PET.

Sources:

  • Society of Nuclear Medicine and Molecular Imaging
  • American Society of Nuclear Cardiology
  • European Association of Nuclear Medicine
  • American College of Nuclear Medicine
  • The Journal of Nuclear Medicine
  • The Journal of Nuclear Cardiology
  • Contify.com